about
Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophagesRasputin, more promiscuous than ever: a review of G3BPThe regulated retrotransposon transcriptome of mammalian cellsDevelopment of a DNA barcode tagging method for monitoring dynamic changes in gene expression by using an ultra high-throughput sequencer.Data-driven normalization strategies for high-throughput quantitative RT-PCR.Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkersMacrophage activation and differentiation signals regulate schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis.Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trialConservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages.Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migrationThe transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line.Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.Peripheral blood monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes.Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation.Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury.Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established BiomarkersCan paracetamol (acetaminophen) be administered to patients with liver impairment?The FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation.CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin.Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease.Salmonella employs multiple mechanisms to subvert the TLR-inducible zinc-mediated antimicrobial response of human macrophages.Expression profiling feline peripheral blood monocytes identifies a transcriptional signature associated with type two diabetes mellitus.The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease.Identifying areas of need relative to liver disease: geographic clustering within a health service district.Update of the FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation.The combination of gene perturbation assay and ChIP-chip reveals functional direct target genes for IRF8 in THP-1 cells.A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations.Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease.ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity.PU.1 and ICSBP control constitutive and IFN-gamma-regulated Tlr9 gene expression in mouse macrophages.Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS.Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages.Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis.Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
P50
Q28294510-C4E969CC-BF3C-4B0A-9286-E1322072EC4CQ28298633-A5BEBC36-C2D0-44FB-A529-97E0E2493353Q29614444-A7BE2B38-71FE-4357-AABD-D44D6DAFC6EEQ33350040-D3E15086-2563-4810-ABF6-D616A7264D02Q33431480-AA41F824-C2FA-48AE-BE06-2885EDE9A82CQ33701694-A6859313-02C9-4BEA-B7CF-7D3E197B2690Q33797705-F64D50C6-4E36-428E-A7AA-1DDBF16A29DEQ33879548-E1C790C8-B3F9-45D9-8F4C-7E12BE422FDAQ33921869-6531580F-43F3-43C8-86A2-FAD89F8399D9Q34263905-C90F1D64-868E-48C6-A51C-436FC92E3DAAQ34750592-D489FECC-EE92-4A5C-A3A8-4EDE756E68F7Q34976601-1DB2F319-3F0A-4435-9471-06EEF8F1AEAEQ35189328-83E0580A-C100-4198-B3E5-9AA5D2DF52C1Q35902870-D3F7FE19-BDB1-4817-AB0E-4F9A92741C1AQ36022067-BA387243-DB28-45F3-BAF7-FD3A9BC27F8AQ36054086-B7A8BE1B-FC9F-4E1C-83E3-7818760BFB9DQ36130230-B4DF4F8C-7E21-477C-9157-6AD0E19D5E02Q36163662-71A02E8C-6BC2-496D-BC55-464A29D74369Q36197398-46E29A8D-F375-4E4A-907E-BA0287F6DCE3Q36802077-28577994-39BD-4901-AC76-4ED0CBE21FDAQ37208716-E7168CAB-7E91-4934-9675-A0CB601DF473Q37277340-CB4E0CAA-5844-49DC-A0E6-D34BE0663203Q38123193-5C6B72C3-5B79-4331-AC41-2B651BB72B48Q38217349-CEF0CD20-78E4-4291-B813-A3A1FEE54FD7Q38535634-123BFC32-26A1-4601-9F11-0CACD1A47521Q38797082-F16D6FB3-F91E-453D-8AF2-04EAA48B07C5Q38835190-1BD98CBC-3AB0-45E8-85B4-AD7B0DA9B7A0Q39311652-6327889A-A7F0-41F5-8CBC-1AB058BC6B43Q39504476-134E4C56-9091-407C-B905-4A507EACA4C5Q39632067-ED87CD3E-1603-438E-BC0A-56B61FB90C78Q39689048-331B8A68-D1FF-44D1-86DC-4366C872F653Q40249893-9C8031DC-F4B6-4C07-9778-2131E0D559E5Q40834810-496F3FCC-6440-430E-87EC-41BD81453701Q42177206-27CBC0AA-0892-4D9C-9D37-B86DE9B2D5CEQ42509604-BB0DB296-114B-43D8-90DF-3CF4C673A742Q43143715-8651E279-351B-45F0-AA6C-2990723CDF67Q46250361-FC4709D1-68A9-4D9A-9551-A335D15E51C1Q46809187-16FAE3DC-D22D-435D-ADF6-6518E4FEED68Q47094159-8D4DCD32-D384-4FFD-B9BD-C939F16F4937Q47627120-540DDBE6-9A6A-4EAD-A904-F417421F6461
P50
description
researcher ORCID ID = 0000-0002-6716-1605
@en
wetenschapper
@nl
name
Katharine M Irvine
@ast
Katharine M Irvine
@en
Katharine M Irvine
@nl
type
label
Katharine M Irvine
@ast
Katharine M Irvine
@en
Katharine M Irvine
@nl
prefLabel
Katharine M Irvine
@ast
Katharine M Irvine
@en
Katharine M Irvine
@nl
P31
P496
0000-0002-6716-1605